Report Detail

Pharma & Healthcare Global PD-1 and PD-L1 Monoclonal Antibodies Market 2023 by Company, Regions, Type and Application, Forecast to 2029

  • RnM4572680
  • |
  • 02 January, 2024
  • |
  • Global
  • |
  • 103 Pages
  • |
  • GIR (Global Info Research)
  • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global PD-1 and PD-L1 Monoclonal Antibodies market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
According to the different tumor immune mechanisms, the most studied immunotherapy currently mainly includes cellular immunotherapy and immune checkpoint inhibitor therapy. Among them, the immune checkpoint inhibitor that can be used clinically has cytotoxic T lymphocyte-associated antigen 4 (cytotoxic T lymphocyte-associated antigen 4). ' lymphocyte associated antigen-4, CTLA-4) and programmed cell death protein-1 (programmed cell death protein-1, PD-1)/programmed cell death-ligand 1 (programmed cell death-ligand 1, PD- L1). This report studies PD-1 and PD-L1 monoclonal antibodies.
The Global Info Research report includes an overview of the development of the PD-1 and PD-L1 Monoclonal Antibodies industry chain, the market status of Lung Cancer Treatment (PD-1 Monoclonal Antibody, PD-L1 Monoclonal Antibody), Melanoma Treatment (PD-1 Monoclonal Antibody, PD-L1 Monoclonal Antibody), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of PD-1 and PD-L1 Monoclonal Antibodies.
Regionally, the report analyzes the PD-1 and PD-L1 Monoclonal Antibodies markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global PD-1 and PD-L1 Monoclonal Antibodies market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the PD-1 and PD-L1 Monoclonal Antibodies market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the PD-1 and PD-L1 Monoclonal Antibodies industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., PD-1 Monoclonal Antibody, PD-L1 Monoclonal Antibody).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the PD-1 and PD-L1 Monoclonal Antibodies market.
Regional Analysis: The report involves examining the PD-1 and PD-L1 Monoclonal Antibodies market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the PD-1 and PD-L1 Monoclonal Antibodies market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to PD-1 and PD-L1 Monoclonal Antibodies:
Company Analysis: Report covers individual PD-1 and PD-L1 Monoclonal Antibodies players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards PD-1 and PD-L1 Monoclonal Antibodies This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Lung Cancer Treatment, Melanoma Treatment).
Technology Analysis: Report covers specific technologies relevant to PD-1 and PD-L1 Monoclonal Antibodies. It assesses the current state, advancements, and potential future developments in PD-1 and PD-L1 Monoclonal Antibodies areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the PD-1 and PD-L1 Monoclonal Antibodies market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
PD-1 and PD-L1 Monoclonal Antibodies market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
PD-1 Monoclonal Antibody
PD-L1 Monoclonal Antibody
Market segment by Application
Lung Cancer Treatment
Melanoma Treatment
Bowel Cancer Treatment
Other
Market segment by players, this report covers
Merck
Bristol-Myers Squibb
Roche
Pfizer
Astrazeneca
Novartis
Biocad
Sanofi/Regeneron Pharmaceuticals
Beigene
Jiangsu Hengrui Pharmaceuticals
Innovent Biologics, Inc.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe PD-1 and PD-L1 Monoclonal Antibodies product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of PD-1 and PD-L1 Monoclonal Antibodies, with revenue, gross margin and global market share of PD-1 and PD-L1 Monoclonal Antibodies from 2018 to 2023.
Chapter 3, the PD-1 and PD-L1 Monoclonal Antibodies competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and PD-1 and PD-L1 Monoclonal Antibodies market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of PD-1 and PD-L1 Monoclonal Antibodies.
Chapter 13, to describe PD-1 and PD-L1 Monoclonal Antibodies research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of PD-1 and PD-L1 Monoclonal Antibodies
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of PD-1 and PD-L1 Monoclonal Antibodies by Type
    • 1.3.1 Overview: Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Type in 2022
    • 1.3.3 PD-1 Monoclonal Antibody
    • 1.3.4 PD-L1 Monoclonal Antibody
  • 1.4 Global PD-1 and PD-L1 Monoclonal Antibodies Market by Application
    • 1.4.1 Overview: Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Lung Cancer Treatment
    • 1.4.3 Melanoma Treatment
    • 1.4.4 Bowel Cancer Treatment
    • 1.4.5 Other
  • 1.5 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size & Forecast
  • 1.6 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast by Region
    • 1.6.1 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region, (2018-2029)
    • 1.6.3 North America PD-1 and PD-L1 Monoclonal Antibodies Market Size and Prospect (2018-2029)
    • 1.6.4 Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Market Size and Prospect (2018-2029)
    • 1.6.6 South America PD-1 and PD-L1 Monoclonal Antibodies Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Merck
    • 2.1.1 Merck Details
    • 2.1.2 Merck Major Business
    • 2.1.3 Merck PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    • 2.1.4 Merck PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Merck Recent Developments and Future Plans
  • 2.2 Bristol-Myers Squibb
    • 2.2.1 Bristol-Myers Squibb Details
    • 2.2.2 Bristol-Myers Squibb Major Business
    • 2.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    • 2.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Bristol-Myers Squibb Recent Developments and Future Plans
  • 2.3 Roche
    • 2.3.1 Roche Details
    • 2.3.2 Roche Major Business
    • 2.3.3 Roche PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    • 2.3.4 Roche PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Roche Recent Developments and Future Plans
  • 2.4 Pfizer
    • 2.4.1 Pfizer Details
    • 2.4.2 Pfizer Major Business
    • 2.4.3 Pfizer PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    • 2.4.4 Pfizer PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Pfizer Recent Developments and Future Plans
  • 2.5 Astrazeneca
    • 2.5.1 Astrazeneca Details
    • 2.5.2 Astrazeneca Major Business
    • 2.5.3 Astrazeneca PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    • 2.5.4 Astrazeneca PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Astrazeneca Recent Developments and Future Plans
  • 2.6 Novartis
    • 2.6.1 Novartis Details
    • 2.6.2 Novartis Major Business
    • 2.6.3 Novartis PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    • 2.6.4 Novartis PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Novartis Recent Developments and Future Plans
  • 2.7 Biocad
    • 2.7.1 Biocad Details
    • 2.7.2 Biocad Major Business
    • 2.7.3 Biocad PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    • 2.7.4 Biocad PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Biocad Recent Developments and Future Plans
  • 2.8 Sanofi/Regeneron Pharmaceuticals
    • 2.8.1 Sanofi/Regeneron Pharmaceuticals Details
    • 2.8.2 Sanofi/Regeneron Pharmaceuticals Major Business
    • 2.8.3 Sanofi/Regeneron Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    • 2.8.4 Sanofi/Regeneron Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Sanofi/Regeneron Pharmaceuticals Recent Developments and Future Plans
  • 2.9 Beigene
    • 2.9.1 Beigene Details
    • 2.9.2 Beigene Major Business
    • 2.9.3 Beigene PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    • 2.9.4 Beigene PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Beigene Recent Developments and Future Plans
  • 2.10 Jiangsu Hengrui Pharmaceuticals
    • 2.10.1 Jiangsu Hengrui Pharmaceuticals Details
    • 2.10.2 Jiangsu Hengrui Pharmaceuticals Major Business
    • 2.10.3 Jiangsu Hengrui Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    • 2.10.4 Jiangsu Hengrui Pharmaceuticals PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments and Future Plans
  • 2.11 Innovent Biologics, Inc.
    • 2.11.1 Innovent Biologics, Inc. Details
    • 2.11.2 Innovent Biologics, Inc. Major Business
    • 2.11.3 Innovent Biologics, Inc. PD-1 and PD-L1 Monoclonal Antibodies Product and Solutions
    • 2.11.4 Innovent Biologics, Inc. PD-1 and PD-L1 Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Innovent Biologics, Inc. Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global PD-1 and PD-L1 Monoclonal Antibodies Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of PD-1 and PD-L1 Monoclonal Antibodies by Company Revenue
    • 3.2.2 Top 3 PD-1 and PD-L1 Monoclonal Antibodies Players Market Share in 2022
    • 3.2.3 Top 6 PD-1 and PD-L1 Monoclonal Antibodies Players Market Share in 2022
  • 3.3 PD-1 and PD-L1 Monoclonal Antibodies Market: Overall Company Footprint Analysis
    • 3.3.1 PD-1 and PD-L1 Monoclonal Antibodies Market: Region Footprint
    • 3.3.2 PD-1 and PD-L1 Monoclonal Antibodies Market: Company Product Type Footprint
    • 3.3.3 PD-1 and PD-L1 Monoclonal Antibodies Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global PD-1 and PD-L1 Monoclonal Antibodies Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global PD-1 and PD-L1 Monoclonal Antibodies Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global PD-1 and PD-L1 Monoclonal Antibodies Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2018-2029)
  • 6.2 North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2018-2029)
  • 6.3 North America PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country
    • 6.3.1 North America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2018-2029)
    • 6.3.2 United States PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)
    • 6.3.3 Canada PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2018-2029)
  • 7.2 Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2018-2029)
  • 7.3 Europe PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country
    • 7.3.1 Europe PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2018-2029)
    • 7.3.2 Germany PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)
    • 7.3.3 France PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)
    • 7.3.5 Russia PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)
    • 7.3.6 Italy PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Market Size by Region
    • 8.3.1 Asia-Pacific PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Region (2018-2029)
    • 8.3.2 China PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)
    • 8.3.3 Japan PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)
    • 8.3.5 India PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)
    • 8.3.7 Australia PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2018-2029)
  • 9.2 South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2018-2029)
  • 9.3 South America PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country
    • 9.3.1 South America PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Market Size by Country
    • 10.3.1 Middle East & Africa PD-1 and PD-L1 Monoclonal Antibodies Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)
    • 10.3.4 UAE PD-1 and PD-L1 Monoclonal Antibodies Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 PD-1 and PD-L1 Monoclonal Antibodies Market Drivers
  • 11.2 PD-1 and PD-L1 Monoclonal Antibodies Market Restraints
  • 11.3 PD-1 and PD-L1 Monoclonal Antibodies Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 PD-1 and PD-L1 Monoclonal Antibodies Industry Chain
  • 12.2 PD-1 and PD-L1 Monoclonal Antibodies Upstream Analysis
  • 12.3 PD-1 and PD-L1 Monoclonal Antibodies Midstream Analysis
  • 12.4 PD-1 and PD-L1 Monoclonal Antibodies Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on PD-1 and PD-L1 Monoclonal Antibodies. Industry analysis & Market Report on PD-1 and PD-L1 Monoclonal Antibodies is a syndicated market report, published as Global PD-1 and PD-L1 Monoclonal Antibodies Market 2023 by Company, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of PD-1 and PD-L1 Monoclonal Antibodies market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,480.00
    $5,220.00
    $6,960.00
    2,745.72
    4,118.58
    5,491.44
    3,215.52
    4,823.28
    6,431.04
    523,635.60
    785,453.40
    1,047,271.20
    288,526.80
    432,790.20
    577,053.60
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report